Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NRx Pharmaceuticals Inc (NRXPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NRXPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.21% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 714.61M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.55 | 52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 |
52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -191.74% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13364027 |
Shares Outstanding - | Shares Floating 13364027 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NRx Pharmaceuticals Inc
Company Overview
History and Background
NRx Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2015. It focuses on developing novel therapeutics for the treatment of central nervous system (CNS) disorders, particularly those associated with suicidal ideation and post-traumatic stress disorder (PTSD).
Core Business Areas
- Therapeutics Development: Development of pharmaceutical products targeting unmet needs in CNS disorders, primarily suicidal depression and PTSD.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
- Drug Commercialization: Seeking regulatory approvals and commercialization pathways for successful drug candidates.
Leadership and Structure
The leadership team includes experienced professionals in drug development, clinical research, and commercialization. Organizational structure includes R&D, clinical operations, and business development functions. Recent leadership changes have occurred, including a new CEO appointment in late 2023.
Top Products and Market Share
Key Offerings
- NRX-101 (D-cycloserine): An oral, fixed-dose combination of D-cycloserine and lurasidone being developed for the treatment of suicidal bipolar depression. Market share is currently 0% as the product is not yet approved. Key competitors include existing treatments for bipolar disorder and depression, such as lithium, antidepressants (SSRIs, SNRIs), and antipsychotics.
- HTX-100 (ketamine): A formulation of ketamine being explored for treatment of suicidal ideation and PTSD. Market share is currently 0% as the product is not yet approved. Key competitors include Spravato (esketamine) from Johnson & Johnson and generic ketamine formulations.
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by increasing prevalence of mental health disorders and unmet needs in treatment. The market includes pharmaceuticals, therapies, and devices. Regulatory hurdles and high development costs are significant challenges.
Positioning
NRx Pharmaceuticals is positioned as an innovator in the CNS space, focusing on severe and underserved conditions like suicidal depression. Their competitive advantage lies in their novel approaches and potential to address unmet needs. They are considered a high-risk, high-reward investment due to the early stage of their product pipeline.
Total Addressable Market (TAM)
The TAM for depression and PTSD treatments is estimated to be in the billions of dollars annually. NRx Pharmaceuticals is positioned to capture a share of this market if their products are approved and successfully commercialized. The exact TAM depends on the specific indication and market penetration.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet medical needs
- Experienced leadership team
- Focus on underserved CNS disorders
- Potentially disruptive technology
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High regulatory risk
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Successful clinical trial results leading to regulatory approval
- Growing awareness and acceptance of mental health treatments
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- VTRS
- TEVA
Competitive Landscape
NRx Pharmaceuticals faces significant competition from established pharmaceutical companies with greater resources and broader product portfolios. NRx's competitive advantage lies in its novel approaches and focus on underserved CNS disorders. However, the company's smaller size and limited resources present a challenge.
Growth Trajectory and Initiatives
Historical Growth: NRx Pharmaceuticals' growth has been primarily in its research and development activities. The company's value is tied to progress in its clinical trials and regulatory approvals.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals for its drug candidates. Analyst estimates vary widely, reflecting the uncertainty of the company's prospects.
Recent Initiatives: Recent initiatives include advancing clinical trials for NRX-101 and HTX-100, seeking partnerships for drug development and commercialization, and exploring new indications for their existing drug candidates. Also the company has been actively raising capital.
Summary
NRx Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on developing novel CNS therapeutics. Their strength lies in innovative drug candidates targeting unmet needs, but they face significant challenges due to limited resources and regulatory hurdles. Successful clinical trial outcomes are critical for their future growth, and they must navigate a competitive landscape dominated by larger pharmaceutical companies. Recent capital raises are essential for the company to continue its development activities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in NRx Pharmaceuticals involves significant risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-01 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.